Rayonier Acquires PotlatchDeltic Deal Expected to Close Soon
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Rayonier (RYN) is acquiring PotlatchDeltic (PCH) in a deal expected to be completed soon, pending final closing conditions. Rayonier will remain in the S&P MidCap 400 post-merger.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on BROS
Wall Street analysts forecast BROS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BROS is 76.64 USD with a low forecast of 63.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 57.440
Low
63.00
Averages
76.64
High
85.00
Current: 57.440
Low
63.00
Averages
76.64
High
85.00
About BROS
Dutch Bros Inc. is an operator and franchiser of drive-thru shops, which is focused on serving hand-crafted beverages. The Company sells a range of customizable hot, iced and blended beverages. Coffee-based beverages include handcraft espresso shots for both hot and cold custom classic and signature coffee beverages. It also sells proprietary coffee-based Freeze blended beverages and cold brew. Its Private Reserve coffee is a 100% Arabica three-bean blend, roasted by the Company in Grants Pass, Oregon or Melissa, Texas facilities. The Company has two segments: Company-operated shops, and Franchising and other. The Company-operated shops segment includes retail coffee shop sales to end consumers. The Franchising and other segment includes bean and product sales to franchise partners and includes the initial franchise fees, royalties, and marketing fees. It has approximately 1,101 shops, of which over 779 are operated by the Company and 322 are franchised, across 26 states.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wells Fargo Raises Starbucks Price Target to $110 Amid Growth Plans
- Price Target Increase: Wells Fargo analyst Zachary Fadem raised Starbucks' price target from $105 to $110 while maintaining an ‘Overweight’ rating, indicating growing market confidence in the company's recovery potential.
- Sales Growth Recovery: Starbucks reported its first U.S. comparable sales growth in two years, yet failed to significantly boost investor sentiment, resulting in a nearly 1% drop in stock price, reflecting cautious market attitudes towards its growth prospects.
- Innovative Service Model: During the investor day, Starbucks introduced its Green Apron Service operating model, aimed at enhancing customer experience through a more comfortable environment and upcoming menu innovations, thereby attracting younger consumers.
- Declining Market Share: According to Consumer Edge data, Starbucks has lost over 4 percentage points of spending share over the past two years, particularly among consumers aged 25-34, highlighting increasing competitive pressure in the younger market segment.
Continue Reading
S&P MidCap and SmallCap Index Changes Announced
- MidCap Addition: TTM Technologies (TTMI) will be added to the S&P MidCap 400 on January 30, 2026, highlighting its recognition in the information technology sector, which is expected to enhance its market liquidity and investor interest.
- MidCap Deletion: Civitas Resources (CIVI) will be removed from the S&P MidCap 400 on the same date, which may impact its stock performance and market confidence, reflecting its relative weakness in the energy sector.
- SmallCap Addition: Amneal Pharmaceuticals (AMRX) will join the S&P SmallCap 600 on January 30, 2026, strengthening its market position in the healthcare industry and likely attracting more investor attention.
- SmallCap Deletion: TTM Technologies (TTMI) will also be removed from the S&P SmallCap 600 on the same date, indicating its poor performance in the small-cap market, which may lead investors to reassess its investment value.
Continue Reading